Integra LifeSciences Reports First Quarter 2025 Financial Results

Integra LifeSciences reported financial results for the first quarter ending March 31, 2025.

First Quarter 2025 Highlights

• First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year.
  
  
• First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.
  
  
• Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact related to the new tariffs.

“We remain laser focused on strengthening our quality systems, improving supply reliability, and driving operational excellence. There remains significant work ahead, but we are continuing to put the processes and people in place to execute on our comprehensive Compliance Master Plan and build a foundation for sustainable performance. With the launch of our Transformation and Program Management Office and the addition of key leadership, including in global operations, we are driving improved accountability and execution across the enterprise to deliver meaningful long-term value for patients, customers, and shareholders,” said Mojdeh Poul, president and chief executive officer.

Click here for the full press release.